RT - Journal Article T1 - Comparison of Resperidon and Haloperidol Efficacy on the General Signs of Schizophrenia JF - USWR YR - 2007 JO - USWR VO - 8 IS - 0 UR - http://rehabilitationj.uswr.ac.ir/article-1-122-en.html SP - 9 EP - 13 K1 - Schizophrenia K1 - Side effects K1 - Resperidon K1 - General signs K1 - Haloperidol AB - Objective: Different studies have indicated that the Resperidon alleviates the general signs of schizophrenics more than Haloperidol. Since there have not been such researche in Iranian populations, we to compared the efficacy of Resperidon (Iran made) and Haloperidol in reducing the general signs of schizophrenia. Materials & Methods: Frothy five schizophrenic patients (based on DSM-IV criteria) who had been admitted in Razi Psychiatric Center were studied in a before – after experimental study. After a 2-week washout period the patients were randomly assigned into Haloperidol (15mg/d) and Resperidon (6mg/d) groups. For each patient the general subscale of Brief Psychiatric Rating Scale (BPRS) and extra pyramidal complication scales were evaluated and recorded at baseline examination weekly for 8 weeks, after initiation of the therapy. The results were analyzed using t-test for paired samples, independent samples t-test and general linear model (GLM) repeated measured as the main variable, two therapeutic methods between subject factor and timing within subject factor in analysis. Results: No significant differences were observe between the mean score of general signs in baseline until fifth week of treatment course (P>0.05). From the sixth week till the end of the study the mean score of general signs were significantly lower in Resperidon group compared to Haloperidol group (P LA eng UL http://rehabilitationj.uswr.ac.ir/article-1-122-en.html M3 ER -